Published in FEBS Lett on May 01, 1998
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer (2010) 1.87
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci (2011) 1.84
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther (2008) 1.16
Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol (2002) 1.10
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol (2008) 1.04
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2. Br J Cancer (2003) 0.91
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia (2002) 0.91
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer (2008) 0.91
APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol (2010) 0.88
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol (2010) 0.85
Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther (2015) 0.84
Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells. J Korean Med Sci (2005) 0.81
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new? Clin Exp Med (2012) 0.80
Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein. Iran J Cancer Prev (2015) 0.78
Encapsulated stem cells for cancer therapy. Biomatter (2013) 0.77
Immunochemical characteristics of a novel cell death receptor and a decoy receptor on granulosa cells of porcine ovarian follicles. Cytotechnology (2000) 0.75
Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma. Adv Healthc Mater (2015) 0.75
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. Drug Des Devel Ther (2015) 0.75
Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell (1990) 8.30
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Anterior opercular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia: Foix-Chavany-Marie syndrome and "automatic voluntary dissociation" revisited. J Neurol (1993) 3.70
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Identification of a Pax paired domain recognition sequence and evidence for DNA-dependent conformational changes. J Biol Chem (1994) 3.22
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Math5 is required for retinal ganglion cell and optic nerve formation. Development (2001) 3.07
An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell (1990) 3.02
Two independent and interactive DNA-binding subdomains of the Pax6 paired domain are regulated by alternative splicing. Genes Dev (1994) 2.99
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene (2006) 2.82
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med (2003) 2.60
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Math5 encodes a murine basic helix-loop-helix transcription factor expressed during early stages of retinal neurogenesis. Development (1998) 2.38
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res (2001) 2.26
Seven polymorphic loci mapping to human chromosomal region 11q22-qter. Genomics (1988) 2.23
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med (1995) 2.08
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
First observation of PeV-energy neutrinos with IceCube. Phys Rev Lett (2013) 2.00
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Letter: Unusual cardiac and neurological reactions to narcotics. Lancet (1973) 1.90
The beta-subunit of follicle-stimulating hormone is deleted in patients with aniridia and Wilms' tumour, allowing a further definition of the WAGR locus. Nature (1986) 1.84
3' deletions cause aniridia by preventing PAX6 gene expression. Proc Natl Acad Sci U S A (2000) 1.78
CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science (2000) 1.77
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature (1991) 1.75
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Culture and characteristics of hormone-responsive neuroblastoma X glioma hybrid cells. Methods Enzymol (1985) 1.70
Turnover of protein-bound phosphorylserine in membrane preparations from ox brain catalysed by intrinsic kinase and phosphatase activity. Biochem J (1971) 1.68
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol (1991) 1.63
Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol (2010) 1.63
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Protein kinase activity in membrane preparations from ox brain. Stimulation of intrinsic activity by adenosine 3':5'-cyclic monophosphate. Biochem J (1973) 1.59
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. J Neurosci (1996) 1.56
Localization of a human Na+,K+-ATPase alpha subunit gene to chromosome 19q12----q13.2 and linkage to the myotonic dystrophy locus. Genomics (1988) 1.55
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
Isolation and mapping of 62 new RFLP markers on human chromosome 11. Am J Hum Genet (1991) 1.52
Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell (1990) 1.52
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology (2005) 1.52
Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol (2003) 1.49
Short rib-polydactyly (SRP) syndromes, types Majewski and Saldino-Noonan. Z Kinderheilkd (1974) 1.48
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
Positive and negative life changes following sexual assault. J Consult Clin Psychol (2001) 1.46
Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol (2002) 1.46
The syndrome of neonatal copper deficiency. Pediatrics (1973) 1.45
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.45
Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.45
Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ (2006) 1.43
Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry (1993) 1.41
MRI features of primary central nervous system lymphomas at presentation. Neurology (2001) 1.40
Elevated levels of fibronectin in the CSF: what do they signify? J Neurol Sci (1992) 1.38
Genomic, transcriptional and mutational analysis of the mouse microphthalmia locus. Genetics (2000) 1.37
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology (2004) 1.36
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol (1998) 1.34
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol (2001) 1.33
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol (1996) 1.33
Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Mol Cell Biol (1996) 1.32
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res (1999) 1.31
Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech (2001) 1.30
BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry (1999) 1.29
Stimulation by cyclic AMP of intrinsic protein kinase activity in ox brain membrane preparations. Nature (1970) 1.29
Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol (1999) 1.28
Genes encoding alpha and beta subunits of Na,K-ATPase are located on three different chromosomes in the mouse. Proc Natl Acad Sci U S A (1987) 1.27
Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol (1995) 1.26
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene (2003) 1.26
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (1992) 1.26
Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene (2000) 1.26
Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. Neurology (2009) 1.25
Breaking symmetry: the marine environment, prey size, and the evolution of asymmetry in cetacean skulls. Anat Rec (Hoboken) (2007) 1.22
Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. J Biol Chem (1993) 1.20
Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology (1997) 1.17
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res (2001) 1.16
Violence and mental illness. Br Med J (Clin Res Ed) (1984) 1.16